| Sep 21 |
Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week
|
| Aug 9 |
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Reported And Analysts Have Been Lifting Their Price Targets
|
| Aug 7 |
Q2 2024 Sangamo Therapeutics Inc Earnings Call
|
| Aug 7 |
Genentech and Sangamo to develop neurodegenerative disease therapies
|
| Aug 6 |
Sangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call Transcript
|
| Aug 6 |
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 6 |
Sangamo Therapeutics GAAP EPS of -$0.18 misses by $0.03, revenue of $0.3M misses by $7.96M
|
| Aug 6 |
Sangamo: Q2 Earnings Snapshot
|
| Aug 6 |
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
|
| Aug 6 |
Roche, Sangamo ink licensing deal for neuro drugs
|
